vs
Side-by-side financial comparison of ENNIS, INC. (EBF) and Vericel Corp (VCEL). Click either name above to swap in a different company.
ENNIS, INC. is the larger business by last-quarter revenue ($100.2M vs $92.9M, roughly 1.1× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 10.8%, a 14.2% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 0.4%). ENNIS, INC. produced more free cash flow last quarter ($15.7M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 1.4%).
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
EBF vs VCEL — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $100.2M | $92.9M |
| Net Profit | $10.8M | $23.2M |
| Gross Margin | 31.9% | 78.7% |
| Operating Margin | 15.0% | 24.1% |
| Net Margin | 10.8% | 25.0% |
| Revenue YoY | 0.4% | 23.3% |
| Net Profit YoY | 6.1% | 17.3% |
| EPS (diluted) | $0.42 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $100.2M | $92.9M | ||
| Q3 25 | $98.7M | $67.5M | ||
| Q2 25 | $97.2M | $63.2M | ||
| Q1 25 | $92.7M | $52.6M | ||
| Q4 24 | $99.8M | $75.4M | ||
| Q3 24 | $99.0M | $57.9M | ||
| Q2 24 | $103.1M | $52.7M | ||
| Q1 24 | $97.4M | $51.3M |
| Q4 25 | $10.8M | $23.2M | ||
| Q3 25 | $13.2M | $5.1M | ||
| Q2 25 | $9.8M | $-553.0K | ||
| Q1 25 | $9.0M | $-11.2M | ||
| Q4 24 | $10.2M | $19.8M | ||
| Q3 24 | $10.3M | $-901.0K | ||
| Q2 24 | $10.7M | $-4.7M | ||
| Q1 24 | $10.1M | $-3.9M |
| Q4 25 | 31.9% | 78.7% | ||
| Q3 25 | 30.5% | 73.5% | ||
| Q2 25 | 31.1% | 73.7% | ||
| Q1 25 | 29.5% | 69.0% | ||
| Q4 24 | 29.3% | 77.6% | ||
| Q3 24 | 30.1% | 71.9% | ||
| Q2 24 | 30.0% | 69.5% | ||
| Q1 24 | 28.4% | 68.9% |
| Q4 25 | 15.0% | 24.1% | ||
| Q3 25 | 12.5% | 5.1% | ||
| Q2 25 | 13.7% | -3.2% | ||
| Q1 25 | 13.0% | -24.3% | ||
| Q4 24 | 13.1% | 24.5% | ||
| Q3 24 | 13.3% | -4.3% | ||
| Q2 24 | 13.3% | -11.5% | ||
| Q1 24 | 13.3% | -10.7% |
| Q4 25 | 10.8% | 25.0% | ||
| Q3 25 | 13.3% | 7.5% | ||
| Q2 25 | 10.1% | -0.9% | ||
| Q1 25 | 9.7% | -21.4% | ||
| Q4 24 | 10.2% | 26.3% | ||
| Q3 24 | 10.4% | -1.6% | ||
| Q2 24 | 10.4% | -8.9% | ||
| Q1 24 | 10.4% | -7.5% |
| Q4 25 | $0.42 | $0.46 | ||
| Q3 25 | $0.51 | $0.10 | ||
| Q2 25 | $0.38 | $-0.01 | ||
| Q1 25 | $0.34 | $-0.23 | ||
| Q4 24 | $0.39 | $0.40 | ||
| Q3 24 | $0.40 | $-0.02 | ||
| Q2 24 | $0.41 | $-0.10 | ||
| Q1 24 | $0.39 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.8M | $354.6M |
| Total Assets | $354.3M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.3M | $137.5M | ||
| Q3 25 | $31.9M | $135.4M | ||
| Q2 25 | $32.6M | $116.9M | ||
| Q1 25 | $72.5M | $112.9M | ||
| Q4 24 | $68.6M | $116.2M | ||
| Q3 24 | $122.6M | $101.7M | ||
| Q2 24 | $123.7M | $102.5M | ||
| Q1 24 | $110.9M | $110.6M |
| Q4 25 | $304.8M | $354.6M | ||
| Q3 25 | $305.4M | $321.9M | ||
| Q2 25 | $301.2M | $306.8M | ||
| Q1 25 | $302.0M | $295.5M | ||
| Q4 24 | $297.7M | $292.0M | ||
| Q3 24 | $358.4M | $257.5M | ||
| Q2 24 | $354.4M | $243.0M | ||
| Q1 24 | $349.8M | $233.9M |
| Q4 25 | $354.3M | $488.0M | ||
| Q3 25 | $361.8M | $453.3M | ||
| Q2 25 | $361.7M | $435.6M | ||
| Q1 25 | $348.9M | $424.6M | ||
| Q4 24 | $346.1M | $432.7M | ||
| Q3 24 | $406.8M | $390.4M | ||
| Q2 24 | $406.2M | $376.8M | ||
| Q1 24 | $399.2M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.4M | $15.0M |
| Free Cash FlowOCF − Capex | $15.7M | $12.8M |
| FCF MarginFCF / Revenue | 15.7% | 13.8% |
| Capex IntensityCapex / Revenue | 0.7% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.52× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $42.5M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.4M | $15.0M | ||
| Q3 25 | $10.5M | $22.1M | ||
| Q2 25 | $8.0M | $8.2M | ||
| Q1 25 | $12.8M | $6.6M | ||
| Q4 24 | $18.2M | $22.2M | ||
| Q3 24 | $11.8M | $10.2M | ||
| Q2 24 | $23.1M | $18.5M | ||
| Q1 24 | $16.6M | $7.2M |
| Q4 25 | $15.7M | $12.8M | ||
| Q3 25 | $9.0M | $19.5M | ||
| Q2 25 | $6.6M | $81.0K | ||
| Q1 25 | $11.1M | $-7.6M | ||
| Q4 24 | $17.5M | $8.5M | ||
| Q3 24 | $10.7M | $-9.2M | ||
| Q2 24 | $20.6M | $1.8M | ||
| Q1 24 | $15.0M | $-6.8M |
| Q4 25 | 15.7% | 13.8% | ||
| Q3 25 | 9.2% | 28.8% | ||
| Q2 25 | 6.8% | 0.1% | ||
| Q1 25 | 12.0% | -14.5% | ||
| Q4 24 | 17.6% | 11.2% | ||
| Q3 24 | 10.8% | -15.9% | ||
| Q2 24 | 20.0% | 3.4% | ||
| Q1 24 | 15.3% | -13.3% |
| Q4 25 | 0.7% | 2.4% | ||
| Q3 25 | 1.4% | 3.9% | ||
| Q2 25 | 1.4% | 12.9% | ||
| Q1 25 | 1.8% | 27.0% | ||
| Q4 24 | 0.6% | 18.3% | ||
| Q3 24 | 1.1% | 33.5% | ||
| Q2 24 | 2.4% | 31.8% | ||
| Q1 24 | 1.7% | 27.3% |
| Q4 25 | 1.52× | 0.65× | ||
| Q3 25 | 0.80× | 4.35× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 1.78× | 1.12× | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.63× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBF
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
